Genotype CC VKORC1 is associated with hypercoagulation and decreasing of fibrinolytic activity in patients with permanent atrial fibrillation

Rubanenko A. O.
PhD, Associate Professor, Chair for Propaedeutics Therapy¹

Dyachkov V. A.
PhD, Associate Professor, Chair for Propaedeutics Therapy¹; Head, Emergency Department²

Kirichenko N. A.
PhD, Associate Professor, Chair for Hospital Therapy¹; Therapeutist, Emergency Department²

Sergeeva T. A.
Therapeutist, Emergency Department²

Shchukin Yu. V.
MD, Professor, Head, Chair for Propaedeutics Therapy¹

1 - Samara state medical university, Samara, Russia
2 - Samara state medical university clinics, Samara, Russia

Rubanenko Anatolii; e-mail: anatolii.rubanenko@gmail.com

None declared.

The study had no sponsorship.

The article assesses association of VKORC1 C1173T genetic polymorphisms and haemostatic indicators in patients with permanent atrial fibrillation. We enrolled in the study 235 patients with coronary artery disease and permanent atrial fibrillation (mean age 66.5±8.3 years). We show that in patients with permanent atrial fibrillation genotype CC VKORC1 is associated with increasing of thrombin activatable fibrinolysis concentration more than 210% and soluble fibrin monomer complexes more than 11 mg%.

genetic polymorphisms, vitamin K epoxide reductase subunit 1, thrombin activatable fibrinolysis inhibitor, atrial fibrillation

10.29234/2308-9113-2019-7-2-1-8

1. Rekomendacii ESC po lecheniyu pacientov s fibrillyaciej predserdij, razrabotannye sovmestno s EACTS [2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS]. [Rossijskij kardiologicheskij zhurnal] Russ J Cardiol. 2017; 147 (7): 7-86. (In Russ.)

2. Rubanenko A.O., Shchukin Yu. V. Genotip SS gena VKORC1 associiruetsya s aktivaciej kaskada koagulyacii i snizheniem fibrinoliticheskoj aktivnosti u pacientov s fibrillyaciej predserdij [VKORC1 CC genotype is associated with activation of the coagulation cascade and reduction of fibrinolytic activity in patients with atrial fibrillation]. Prakticheskaya medicina [Practical medicine] 2015; 88 (3-2): 53-55. (In Russ.)

3.Rubanenko A.O., Shchukin Yu. V. Faktory, associirovannye s razvitiem tromboza ushka levogo predserdiya u bol'nyh s postoyannoj formoj fibrillyacii predserdij [Factors associated with thrombosis of the left atrial appendage in patients with chronic atrial fibrillation]. Klinicheskaya medicina [Clinical medicine] 2014. 92 (11): 29-34. (In Russ.)

4. Danese E., Montagnana M., Cervelin G., Lippi G. Hypercoagulability, D-dimer and atrial fibrillation: an overview of biological and clinical evidence. Ann Med 2014; (27): 1-8. doi:10.3109/07853890.2014.912835.

5. Hijazi Z., Oldgren J., Siegbahn A., Granger C.B. et al. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J. 2013; 34(20): 1475-80. doi: 10.1093/eurheartj/eht024.

6. Matusik P.T., Matusik P.S., Kornacewicz-Jach Z. et al. Elevated NT-proBNP is associated with unfavorably altered plasma fibrin clot properties in atrial fibrillation. Int J Cardiol. 2017; (243): 244-250. doi: 10.1016/j.ijcard.2017.05.060

7. Makar-Aušperger K., Krzelj K., Lovriс Benсiс M. et al. Warfarin Dosing According to the Genotype-guided Algorithm is Most Beneficial in Patients with Atrial Fibrillation: A Randomized Parallel Group Trial. Ther Drug Monit. 2018; 40(3):362-368. doi: 10.1097/FTD.0000000000000501.

8. Nahar R., Saxena R., Deb R.et al. CYP2C9, VKORC1, CYP4F2, ABCB1 and F5 variants: Influence on quality of long-term anticoagulation. Pharmacol Rep.2014; 66(2): 243-9. doi: 10.1016/j.pharep.2013.09.006.

9. Pang H., Zhang C., Liu F. et al. Reduced thrombin activatable fibrinolysis inhibitor and enhanced inflammatory markers in ACS. Minerva Cardioangiol. 2016; Oct 21.

10. Pirmohamed M., Burnside G., Eriksson N. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med.2013. 369(24): 2294-303. doi: 10.1056/NEJMoa1311386.

11. Shaw K, Amstutz U, Kim R.B. et al. Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. Ther Drug Monit. 2015; 37(4):428-36.

12. Shi J., Zhi P., Chen J. et al. Genetic variations in the thrombin-activatable fibrinolysis inhibitor gene and risk of cardiovascular disease: a systematic review and meta-analysis. Thromb Res. 2014; 134(3): 610-6. doi: 10.1016/j.thromres.2014.06.023

13. Tang W., Shi Q.P., Ding F. et al. Impact of VKORC1 gene polymorphisms on warfarin maintenance dosage: A novel systematic review and meta-analysis of 53 studies. Int J Clin Pharmacol Ther. 2017; 55(4):304-321. doi: 10.5414/CP202833.

14. Vesa S.C., Trifa A.P., Crişan S. et al. VKORC1-1639 G>A Polymorphism in Romanian Patients with Deep Vein Thrombosis. Clin Appl Thromb Hemost. 2016; 22(8):760-764.

15. Wang W., Ma H., Lu L. et al. Association between thrombin-activatable fibrinolysis inhibitor gene polymorphisms and venous thrombosis risk: a meta-analysis. Blood CoagulFibrinolysis. 2016; 27(4):419-30. doi: 10.1097/MBC.0000000000000475.